Hendrika Bootsma

Q: What Schools Are Affiliated With Hendrika Bootsma

Hendrika Bootsma is affiliated with the following schools: University of Amsterdam, University of Groningen

Hendrika Bootsma's AcademicInfluence.com Rankings

Hendrika Bootsma

Biology

#11525

World Rank

#14927

Historical Rank

Virology

#277

World Rank

#284

Historical Rank

Immunology

#741

World Rank

#763

Historical Rank

biology Degrees

Download Badge

Biology

Hendrika Bootsma's Degrees

PhD Biomedical Sciences University of Amsterdam
Masters Biomedical Sciences University of Amsterdam
Bachelors Biomedical Sciences University of Amsterdam

Why Is Hendrika Bootsma Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Hendrika Bootsma's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndrome (2009) (727)
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force (2014) (526)
Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. (2005) (513)
Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial. (2010) (444)
Sjögren syndrome (2023) (442)
EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjögren's syndrome (2011) (373)
Prevention of relapses in systemic lupus erythematosus (1995) (272)
A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS) (2016) (259)
EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide (2015) (236)
Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI) (2014) (231)
EULAR recommendations for the management of Sjögren’s syndrome with topical and systemic therapies (2019) (221)
Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI) (2014) (220)
Skewed distribution of IgG Fc receptor IIa (CD32) polymorphism is associated with renal disease in systemic lupus erythematosus patients. (1995) (219)
Characterization of systemic disease in primary Sjögren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. (2015) (211)
Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study) (2014) (207)
Health-related quality of life, employment and disability in patients with Sjogren's syndrome. (2009) (200)
Changes in antibodies to C1q predict renal relapses in systemic lupus erythematosus. (1995) (171)
Standardisation of labial salivary gland histopathology in clinical trials in primary Sjögren's syndrome (2016) (169)
Levels of soluble VCAM‐1, soluble ICAM‐1, and soluble E‐selectin during disease exacerbations in patients with systemic lupus erythematosus (SLE); a long term prospective study (1994) (152)
Progression of salivary gland dysfunction in patients with Sjögren’s syndrome (2006) (147)
Parotid gland biopsy compared with labial biopsy in the diagnosis of patients with primary Sjogren's syndrome. (2007) (136)
Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjögren's syndrome. (2009) (135)
Sialometry and sialochemistry: diagnostic tools for Sjögren's syndrome (2001) (134)
Traditional and non-traditional risk factors contribute to the development of accelerated atherosclerosis in patients with systemic lupus erythematosus (2006) (134)
Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sjögren Project Consortium (2016) (125)
Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjögren’s syndrome and associated MALT lymphoma (2004) (121)
B-cell hyperactivity in primary Sjögren's syndrome (2014) (117)
Early diagnosis of primary Sjögren’s syndrome: EULAR-SS task force clinical recommendations (2016) (116)
Is salivary gland ultrasonography a useful tool in Sjögren's syndrome? A systematic review. (2016) (116)
Shared gut, but distinct oral microbiota composition in primary Sjögren's syndrome and systemic lupus erythematosus. (2019) (115)
How immunological profile drives clinical phenotype of primary Sjögren's syndrome at diagnosis: analysis of 10,500 patients (Sjögren Big Data Project). (2018) (115)
Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab (2011) (111)
The predictive value of fluctuations in IgM and IgG class anti-dsDNA antibodies for relapses in systemic lupus erythematosus. A prospective long term observation (1997) (108)
Sialometry and sialochemistry: a non-invasive approach for diagnosing Sjögren's syndrome (2002) (108)
Th17 cells in primary Sjögren's syndrome: Pathogenicity and plasticity. (2018) (106)
Systemic sclerosis and its pulmonary complications in The Netherlands: an epidemiological study (2008) (103)
Treatment of primary Sjögren syndrome with rituximab: extended follow-up, safety and efficacy of retreatment (2009) (101)
Attenuation of Follicular Helper T Cell–Dependent B Cell Hyperactivity by Abatacept Treatment in Primary Sjögren's Syndrome (2017) (99)
Effect of dehydroepiandrosterone administration on fatigue, well-being, and functioning in women with primary Sjögren syndrome: a randomised controlled trial (2007) (96)
Classification criteria for Sjögren's syndrome: we actually need to definitively resolve the long debate on the issue (2012) (93)
Serum amyloid P component binds to late apoptotic cells and mediates their uptake by monocyte-derived macrophages. (2003) (93)
Ultrasonography of major salivary glands compared with parotid and labial gland biopsy and classification criteria in patients with clinically suspected primary Sjögren’s syndrome (2017) (91)
The microbiome-systemic diseases connection. (2016) (86)
Towards personalised treatment in primary Sjögren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment (2016) (83)
Outcome measures for primary Sjögren's syndrome: a comprehensive review. (2014) (82)
Salivary gland ultrasound abnormalities in primary Sjögren’s syndrome: consensual US-SG core items definition and reliability (2017) (80)
Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjögren's syndrome: data from a placebo-controlled clinical trial (2012) (78)
Treatment of Mucosa-associated Lymphoid Tissue Lymphoma in Sjögren’s Syndrome: A Retrospective Clinical Study (2011) (78)
Systems biology analysis of Sjögren's syndrome and mucosa-associated lymphoid tissue lymphoma in parotid glands. (2009) (76)
Enhanced Bruton's Tyrosine Kinase Activity in Peripheral Blood B Lymphocytes From Patients With Autoimmune Disease (2017) (75)
Early atherosclerosis in systemic sclerosis and its relation to disease or traditional risk factors (2008) (74)
Reduction in Spinal Radiographic Progression in Ankylosing Spondylitis Patients Receiving Prolonged Treatment With Tumor Necrosis Factor Inhibitors (2016) (73)
Presence of anticitrullinated protein antibodies in a large population-based cohort from the Netherlands (2017) (71)
Macrovascular disease and atherosclerosis in SSc. (2008) (70)
Abatacept attenuates T follicular helper-cell-dependent B-cell hyperactivity in primary Sjögren's syndrome. (2017) (68)
Diagnostic properties of ultrasound of major salivary glands in Sjögren's syndrome: a meta-analysis. (2015) (68)
Obesity Is Common in Axial Spondyloarthritis and Is Associated with Poor Clinical Outcome (2016) (64)
Mycophenolate mofetil prevents a clinical relapse in patients with systemic lupus erythematosus at risk (2003) (63)
Development of the Sjögren's Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy. (2015) (62)
Sjögren's syndrome and localized nodular cutaneous amyloidosis: coincidence or a distinct clinical entity? (2007) (62)
Germinal centres in diagnostic labial gland biopsies of patients with primary Sjögren’s syndrome are not predictive for parotid MALT lymphoma development (2017) (62)
IgG subclass distribution of autoantibodies differs between renal and extra-renal relapses in patients with systemic lupus erythematosus. (2002) (61)
Parotid sialography for diagnosing Sjögren syndrome. (2002) (61)
B cell reconstitution and T helper cell balance after rituximab treatment of active primary Sjögren's syndrome: a double-blind, placebo-controlled study. (2011) (61)
Development of the ClinESSDAI: a clinical score without biological domain. A tool for biological studies (2016) (60)
The impact of primary Sjögren's syndrome on female sexual function. (2014) (60)
T cells in primary Sjögren’s syndrome: targets for early intervention (2019) (59)
Long-term follow-up of 46 patients with anti-(U1)snRNP antibodies. (1994) (56)
Persistence of immunoglobulin-producing cells in parotid salivary glands of patients with primary Sjögren's syndrome after B cell depletion therapy (2012) (54)
2021 DORIS definition of remission in SLE: final recommendations from an international task force (2021) (53)
The value of rituximab treatment in primary Sjögren's syndrome. (2017) (53)
Outcome measures for primary Sjögren's syndrome. (2012) (52)
B Cell Depletion Therapy Normalizes Circulating Follicular Th Cells in Primary Sjögren Syndrome (2017) (51)
Antineutrophil cytoplasmic antibodies in systemic lupus erythematosus. (1996) (51)
Systems analysis of primary Sjögren's syndrome pathogenesis in salivary glands identifies shared pathways in human and a mouse model (2012) (51)
EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial (2013) (49)
Increased frequency of CD16+ monocytes and the presence of activated dendritic cells in salivary glands in primary Sjögren syndrome (2008) (48)
Spinal Radiographic Progression in Patients with Ankylosing Spondylitis Treated with TNF-α Blocking Therapy: A Prospective Longitudinal Observational Cohort Study (2015) (47)
High mobility group box 1 skews macrophage polarization and negatively influences phagocytosis of apoptotic cells. (2016) (46)
Toward new classification criteria for Sjögren's syndrome? (2013) (46)
Epidemiological profile and north-south gradient driving baseline systemic involvement of primary Sjögren's syndrome. (2019) (44)
Abatacept treatment for patients with early active primary Sjögren's syndrome: a single-centre, randomised, double-blind, placebo-controlled, phase 3 trial (ASAP-III study) (2020) (44)
Parotid gland biopsy compared with labial biopsy in the diagnosis of patients with primary Sjogren's syndrome (2006) (43)
FcRL4+ B-cells in salivary glands of primary Sjögren's syndrome patients. (2017) (43)
Dysbiosis of the buccal mucosa microbiome in primary Sjögren’s syndrome patients (2018) (43)
Primary pulmonary hypertension in a patient with systemic lupus erythematosus: partial improvement with cyclophosphamide. (1993) (43)
Predominantly proinflammatory cytokines decrease after B cell depletion therapy in patients with primary Sjögren's syndrome (2013) (42)
Immune regulation and B-cell depletion therapy in patients with primary Sjögren's syndrome. (2012) (41)
Epithelial–immune cell interplay in primary Sjögren syndrome salivary gland pathogenesis (2021) (41)
Bosentan therapy for patients with severe Raynaud’s phenomenon in systemic sclerosis (2007) (41)
The Future of Biologic Agents in the Treatment of Sjögren’s Syndrome (2007) (40)
Abatacept treatment of patients with primary Sjögren's syndrome results in a decrease of germinal centres in salivary gland tissue. (2017) (38)
Efficacy of Epratuzumab, an Anti‐CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome (2018) (38)
Ankylosing spondylitis patients at risk of poor radiographic outcome show diminishing spinal radiographic progression during long-term treatment with TNF-α inhibitors (2017) (38)
Salivary Gland Stem Cells Age Prematurely in Primary Sjögren's Syndrome (2018) (38)
Efficacy and safety of abatacept in active primary Sjögren’s syndrome: results of a phase III, randomised, placebo-controlled trial (2020) (38)
Lacrimal Punctum Occlusion in the Treatment of Severe Keratoconjunctivitis Sicca Caused by Sjögren Syndrome: A Uniocular Evaluation (2007) (37)
Clinical Risk Factors for the Presence and Development of Vertebral Fractures in Patients With Ankylosing Spondylitis (2017) (37)
Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sjögren’s syndrome (2019) (37)
Weight of salivary gland ultrasonography compared to other items of the 2016 ACR/EULAR classification criteria for Primary Sjögren’s syndrome (2020) (37)
Serum amyloid P component levels are not decreased in patients with systemic lupus erythematosus and do not rise during an acute phase reaction (2004) (37)
Reduced salivary secretion contributes more to changes in the oral microbiome of patients with primary Sjögren’s syndrome than underlying disease (2018) (36)
No effects of bosentan on microvasculature in patients with limited cutaneous systemic sclerosis (2009) (35)
What have we learned from clinical trials in primary Sjögren's syndrome about pathogenesis? (2011) (35)
Oral and ocular manifestations in Sjögren's syndrome. (2002) (35)
Treatment of primary Sjögren's syndrome with anti-CD20 therapy (rituximab). A feasible approach or just a starting point? (2011) (34)
Ig Gene Analysis Reveals Altered Selective Pressures on Ig-Producing Cells in Parotid Glands of Primary Sjögren’s Syndrome Patients (2015) (33)
Comparison of lacrimal and salivary gland involvement in Sjögren's syndrome. (2003) (32)
Psychological and somatic predictors of perceived and measured ocular dryness of patients with primary Sjögren's syndrome. (2005) (32)
Anti-double stranded DNA antibodies in systemic lupus erythematosus: detection and clinical relevance of IgM-class antibodies. (1996) (31)
Dental Implants in Patients with Sjögren's Syndrome. (2016) (31)
Bronchoalveolar lavage cell analysis and lung function impairment in patients with systemic lupus erythematosus (SLE) (1993) (30)
Imaging in Primary Sjögren’s Syndrome (2020) (29)
Scoring hypoechogenic areas in one parotid and one submandibular gland increases feasibility of ultrasound in primary Sjögren’s syndrome (2017) (29)
Patient-tailored dose reduction of TNF-α blocking agents in ankylosing spondylitis patients with stable low disease activity in daily clinical practice. (2015) (29)
Psychological profiles in patients with Sjögren's syndrome related to fatigue: a cluster analysis. (2015) (29)
Current and future challenges in primary Sjögren's syndrome. (2012) (29)
Juvenile Sjögren's Syndrome: Clinical Characteristics With Focus on Salivary Gland Ultrasonography (2019) (28)
Parotid Gland Biopsy, the Alternative Way to Diagnose Sjögren Syndrome. (2016) (28)
Incorporation of Salivary Gland Ultrasonography Into the American College of Rheumatology/European League Against Rheumatism Criteria for Primary Sjögren's Syndrome (2020) (26)
Higher Bone Turnover Is Related to Spinal Radiographic Damage and Low Bone Mineral Density in Ankylosing Spondylitis Patients with Active Disease: A Cross-Sectional Analysis (2014) (26)
Incorporation of salivary gland ultrasonography into the ACR-EULAR criteria for primary Sjögren's syndrome. (2019) (26)
Efficacy of retreatment with rituximab in patients with primary Sjögren's syndrome. (2015) (26)
Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS): development and validation of a novel outcome measure (2021) (25)
Precapillary Pulmonary Hypertension Dramatically Improved With High Doses of Corticosteroids During Systemic Lupus Erythematosus - Reply (1994) (25)
Physical activity and physical activity cognitions are potential factors maintaining fatigue in patients with primary Sjögren's syndrome (2011) (25)
Is the T Follicular Regulatory:Follicular Helper T Cell Ratio in Blood a Biomarker for Ectopic Lymphoid Structure Formation in Sjögren's Syndrome? Comment on the Article by Fonseca et al (2018) (25)
Gene expression profiling of epithelium-associated FcRL4+ B cells in primary Sjögren’s syndrome reveals a pathogenic signature (2020) (24)
Quantitation of Autoantibodies in Systemic Autoimmune Diseases: Clinically Useful? (2006) (23)
How to assess treatment efficacy in Sjögren's syndrome? (2012) (23)
In primary Sjögren's syndrome high absolute numbers and proportions of B cells in parotid glands predict responsiveness to rituximab as defined by ESSDAI, but not by SSRI (2016) (22)
Host–microflora interaction in Systemic Lupus Erythematosus (SLE): colonization resistance of the indigenous bacteria of the intestinal tract (1994) (22)
Validation of the ACR-EULAR criteria for primary Sjögren’s syndrome in a Dutch prospective diagnostic cohort (2018) (21)
Sjögren’s Syndrome in Older Patients (2013) (21)
Serum immunoglobulin free light chains are sensitive biomarkers for monitoring disease activity and treatment response in primary Sjögren’s syndrome (2018) (20)
Auto-antibodies to double-stranded DNA as biomarker in systemic lupus erythematosus: comparison of different assays during quiescent and active disease (2017) (20)
Need for consensus guidelines to standardise the assessment of germinal centres and other histopathological parameters in salivary gland tissue of patients with primary Sjögren's syndrome (2016) (20)
Ultrasound of the Major Salivary Glands is a Reliable Imaging Technique in Patients with Clinically Suspected Primary Sjögren’s Syndrome (2017) (20)
Serum dehydroepiandrosterone sulphate levels and laboratory and clinical parameters indicating expression of disease are not associated with fatigue, well-being and functioning in patients with primary Sjögren's syndrome. (2011) (19)
Aging and Immunopathology in Primary Sjögren's Syndrome. (2015) (19)
Interferon score is increased in incomplete systemic lupus erythematosus and correlates with myxovirus-resistance protein A in blood and skin (2019) (19)
Ten years of the ESSDAI: is it fit for purpose? (2020) (19)
One year in review 2020: comorbidities, diagnosis and treatment of primary Sjögren's syndrome. (2020) (19)
Progenitor cell niche senescence reflects pathology of the parotid salivary gland in primary Sjögren’s syndrome (2020) (19)
Dysregulation of NF-kB in glandular epithelial cells results in Sjögren’s-like features (2018) (18)
Dealing with emotions when the ability to cry is hampered: emotion processing and regulation in patients with primary Sjögren's syndrome. (2012) (17)
Abnormal Nailfold Capillaroscopy Is Common in Patients with Connective Tissue Disease and Associated with Abnormal Pulmonary Function Tests (2018) (17)
Long-term drug survival and clinical effectiveness of etanercept treatment in patients with ankylosing spondylitis in daily clinical practice. (2017) (17)
Small-molecule inhibitors and the salivary gland epithelium in Sjögren’s syndrome (2019) (16)
Simultaneous presentation of sarcoidosis and Sjögren's syndrome. (2001) (16)
Radiographic damage and progression of the cervical spine in ankylosing spondylitis patients treated with TNF-α inhibitors: Facet joints vs. vertebral bodies. (2017) (16)
Ankylosing spondylitis disease activity score is related to NSAID use, especially in patients treated with TNF-α inhibitors (2018) (15)
Presence of intraepithelial B-lymphocytes is associated with the formation of lymphoepithelial lesions in salivary glands of primary Sjögren's syndrome patients. (2019) (15)
Detailed Analysis of the Articular Domain in Patients with Primary Sjögren Syndrome (2017) (15)
Rituximab treatment in primary Sjogren's syndrome : A double-blind placebo controlled trial (2008) (15)
OP0039 EFFICACY AND SAFETY OF ABATACEPT IN ACTIVE PRIMARY SJÖGREN’S SYNDROME: RESULTS OF A RANDOMISED PLACEBO-CONTROLLED PHASE III TRIAL (2019) (14)
Physical fatigue characterises patient experience of primary Sjögren's syndrome. (2017) (14)
Standardisation of the detection of germinal centres in salivary gland biopsies of patients with primary Sjögren’s syndrome is needed to assess their clinical relevance (2017) (14)
The Transcriptome of Paired Major and Minor Salivary Gland Tissue in Patients With Primary Sjögren’s Syndrome (2021) (14)
The parotid gland connection: ultrasound and biopsies in primary Sjögren’s syndrome (2017) (14)
Clinical significance of quantitative immunohistology in labial salivary glands for diagnosing Sjogren's syndrome. (2006) (13)
Advances, limitations and future perspectives in the diagnosis and management of dry eye in Sjögren's syndrome. (2020) (13)
Rituximab treatment in primary Sjogren's syndrome (2005) (13)
Incomplete Systemic Lupus Erythematosus: What Remains After Application of American College of Rheumatology and Systemic Lupus International Collaborating Clinics criteria? (2020) (13)
Autoantibodies to box A of high mobility group box 1 in systemic lupus erythematosus (2017) (13)
Acquisition of N-Glycosylation Sites in Immunoglobulin Heavy Chain Genes During Local Expansion in Parotid Salivary Glands of Primary Sjögren Patients (2018) (13)
High prevalence of hip involvement and decrease in inflammatory ultrasound lesions during tumour necrosis factor-α blocking therapy in ankylosing spondylitis. (2019) (13)
Rapid free thiol rebound is a physiological response following cold‐induced vasoconstriction in healthy humans, primary Raynaud and systemic sclerosis (2019) (13)
Digital ischaemia during cooling is independently related to nailfold capillaroscopic pattern in patients with Raynaud's phenomenon. (2016) (13)
From incomplete to complete systemic lupus erythematosus; A review of the predictive serological immune markers. (2020) (13)
Incorporating assessment of the cervical facet joints in the modified Stoke ankylosing spondylitis spine score is of additional value in the evaluation of spinal radiographic outcome in ankylosing spondylitis (2017) (13)
Childhood-onset of primary Sjögren's syndrome: phenotypic characterization at diagnosis of 158 children. (2021) (12)
Ultrasound Evaluation of the Entheses in Daily Clinical Practice during Tumor Necrosis Factor-α Blocking Therapy in Patients with Ankylosing Spondylitis (2017) (12)
Repertoire Analysis of B-Cells Located in Striated Ducts of Salivary Glands of Patients With Sjögren's Syndrome (2020) (12)
Editorial: Rituximab in the Treatment of Sjögren's Syndrome: Is It the Right or Wrong Drug? (2017) (12)
Blocking T cell co-stimulation in primary Sjögren's syndrome: rationale, clinical efficacy and modulation of peripheral and salivary gland biomarkers. (2020) (12)
Radiographic vertebral fractures develop in patients with ankylosing spondylitis during 4 years of TNF-α blocking therapy. (2016) (12)
Development and preliminary validation of the Sjögren’s Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjögren’s syndrome (2022) (12)
University of Groningen Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjogren's Syndrome Post Hoc Analyses From the EMBODY Trials (2018) (12)
02.45 Enhanced bruton’s tyrosine kinase activity in peripheral blood b lymphocytes of autoimmune disease patients (2017) (12)
Germinal Centers in Diagnostic Biopsies of Patients With Primary Sjögren's Syndrome Are Not a Risk Factor for Non‐Hodgkin's Lymphoma but a Reflection of High Disease Activity: Comment on the Article by Sène et al (2018) (12)
Safety of treatments for primary Sjögren’s syndrome (2016) (11)
Epidemiologic Subsets Drive a Differentiated Clinical and Immunological Presentation of Primary Sjogren Syndrome : Analysis of 9302 Patients from the Big Data International Sjogren Cohort (2017) (11)
Vaginal dryness in primary Sjögren’s syndrome: a histopathological case–control study (2020) (11)
Hydroxychloroquine Suppresses Interferon-inducible Genes and B Cell Activating Factor in Patients With Incomplete and New-onset Systemic Lupus Erythematosus (2020) (11)
Treatment approaches in primary Sjogren syndrome. (2010) (11)
Regional Specific Changes of Cerebral Metabolism in Systemic Lupus erythematosus Identified by Positron Emission Tomography (1999) (11)
Lack of Conventional Acinar Cells in Parotid Salivary Gland of Patient Taking an Anti-PD-L1 Immune Checkpoint Inhibitor (2020) (11)
Biomarkers: New biomarker for Sjögren's syndrome—time to treat patients (2013) (11)
Male and female patients with axial spondyloarthritis experience disease activity, physical function and quality of life differently: results from the Groningen Leeuwarden Axial Spondyloarthritis cohort. (2015) (11)
Systemic phenotype related to primary Sjögren's syndrome in 279 patients carrying isolated anti-La/SSB antibodies. (2020) (11)
Autoimmune congenital heart block and primary Sjögren's syndrome: characterisation and outcomes of 49 cases. (2020) (10)
SARS-CoV-2 infection in patients with primary Sjögren syndrome: characterization and outcomes of 51 patients (2020) (10)
Usefulness of the SLICC/ACR damage index in patients with systemic lupus erythematosus. (1997) (10)
Host-microflora interaction in systemic lupus erythematosus (SLE): circulating antibodies to the indigenous bacteria of the intestinal tract (1995) (10)
Although female patients with ankylosing spondylitis score worse on disease activity than male patients and improvement in disease activity is comparable, male patients show more radiographic progression during treatment with TNF-α inhibitors. (2019) (10)
Comment on: Auto-antibodies to double-stranded DNA as biomarker in systemic lupus erythematosus: comparison of different assays during quiescent and active disease: reply. (2017) (9)
OP0217 Defining Disease Activity Sates and Minimal Clinically Important Improvement (MCII) with the EULAR Primary SjÖGren's Syndrome Disease Activity Index (ESSDAI) (2014) (9)
Normal vaginal microbiome in women with primary Sjögren’s syndrome-associated vaginal dryness (2018) (9)
OP0135 SAFETY AND EFFICACY OF SUBCUTANEOUS BELIMUMAB AND INTRAVENOUS RITUXIMAB COMBINATION IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME: A PHASE 2, RANDOMISED, PLACEBO-CONTROLLED 68-WEEK STUDY (2021) (9)
SAT0379 Reduction in Spinal Radiographic Progression in Ankylosing Spondylitis Patients Receiving Prolonged Treatment with Tnf Inhibitors: Results from The Glas Cohort (2016) (9)
Pulmonary medium vessel vasculitis in an 11 year old boy: Hughes Stovin syndrome as a variant of polyarteritis nodosa? (2011) (9)
Connective tissue diseases: Refining the classification criteria for primary Sjögren syndrome (2016) (9)
OP0045 ABATACEPT TREATMENT OF PATIENTS WITH EARLY ACTIVE PRIMARY SJÖGREN’S SYNDROME – A RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED PHASE (2019) (9)
Can ultrasound of the major salivary glands assess histopathological changes induced by treatment with rituximab in primary Sjögren’s syndrome? (2018) (8)
Laboratory tests as predictors of flares in systemic lupus erythematosus: comment on the article by Esdaile et al. (1997) (8)
CD27-CD38lowCD21low B-Cells Are Increased in Axial Spondyloarthritis (2021) (8)
Incomplete systemic lupus erythematosus - what remains after application of ACR and SLICC criteria? (2019) (8)
Decreased capillary permeability and capillary density in patients with systemic sclerosis using large-window sodium fluorescein videodensitometry of the ankle. (2008) (8)
OP0112 Abatacept Treatment Reduces Disease Activity in Early Primary Sjögren’s Syndrome (Phase II Open Label Asap Study) (2013) (8)
Clinical Phenotyping of Primary Sjögren Syndrome Patients Using Salivary Gland Ultrasonography: Data From the RESULT Cohort (2020) (7)
Crying Without Tears: Dimensions of Crying and Relations With Ocular Dryness and Mental Well-Being in Patients With Sjögren’s Syndrome (2016) (7)
Senescent Stem and Transient Amplifying Cells in Crohn’s Disease Intestine (2019) (7)
Bcl6 for identification of germinal centres in salivary gland biopsies in primary Sjögren's syndrome (2020) (7)
Skin Autofluorescence, as Marker of Accumulation of Advanced Glycation Endproducts and of Cumulative Metabolic Stress, Is Not Increased in Patients with Systemic Sclerosis (2011) (7)
Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium. (2021) (6)
FRI0303 Validation of eular primary sjögren’s syndrome disease activity and patient indexes (2012) (6)
Central sensitization, illness perception and obesity should be considered when interpreting disease activity in axial spondyloarthritis (2021) (6)
Central sensitization has major impact on quality of life in patients with axial spondyloarthritis. (2021) (6)
Treatment of resistant Raynaud’s phenomenon with single-port thoracoscopic sympathicotomy: a novel minimally invasive endoscopic technique (2019) (6)
Corrigendum: Characterization of systemic disease in primary Sjögren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements [Rheumatology, 54, (2015) (2230-2238)] DOI: 10.1093/rheumatology/kev200 (2017) (6)
Microbiome in Sjögren’s syndrome: here we are (2020) (6)
Primary sialoangiectasia--a diagnostic pitfall in Sjögren's syndrome: case report. (1999) (6)
Checkpoint inhibition-induced sicca: a type II interferonopathy? (2020) (6)
SP0190 2019 EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF SJöGREN”S SYNDROME WITH TOPICAL AND SYSTEMIC THERAPIES (2019) (6)
Histopathology, salivary flow and ultrasonography of the parotid gland: three complementary measurements in primary Sjögren’s syndrome (2021) (6)
Longitudinal analysis of varicella-zoster virus-specific antibodies in systemic lupus erythematosus: No association with subclinical viral reactivations or lupus disease activity (2018) (6)
SAT0170 COMPOSITE OF RELEVANT ENDPOINTS FOR SJÖGREN’S SYNDROME (CRESS) (2020) (5)
Engineered IgG-targets identify clinically and pathophysiologically relevant rheumatoid factor epitopes. (2020) (5)
Treatment of MALT lymphoma in Sjogren's syndrome (2006) (5)
A new class of lupus nephropathy associated with antiphospholipid antibodies. (1994) (5)
Practical guidelines for the early diagnosis of Sjögren's syndrome in primary healthcare. (2021) (4)
The mSQUASH; a valid, reliable and responsive questionnaire for daily physical activity in patients with axial spondyloarthritis. (2021) (4)
Rituximab (anti-CD20) for the treatment of primary Sjogren's syndrome. (2004) (4)
Chapter 12 – Management of Sjögren's Syndrome (2010) (4)
Mixed connective tissue disease--a farewell? (1993) (4)
Pharmacotherapy for managing extraglandular symptoms of primary Sjögren’s syndrome (2015) (4)
S I SIALOMETRY AND SIALOCHEMISTRY : DIAGNOSTIC TOOLS IN SJÖGREN ’ S SYNDROME (2001) (4)
Therapeutic Recommendations for the Management of Older Adult Patients with Sjögren’s Syndrome (2021) (3)
AB0164 Numbers of b-lymphocytes increase when formation of lymphoepithelial lesions progresses in salivary glands of primary sjögren’s syndrome patients (2018) (3)
FRI0421 Development of Clinessdai Score (Clinical Eular Sjögren's Syndrome Disease Activity Index) Without Biological Domain: A Tool For Biological Studies (2015) (3)
Pulmonary involvement in primary Sjögren’s syndrome, as measured by the ESSDAI (2020) (3)
β-Adrenergic signaling induces Notch-mediated salivary gland progenitor cell control (2021) (3)
Pulmonary arterial hypertension in systemic lupus erythematosus: should we bother? (2009) (3)
A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren’s syndrome (2022) (3)
Sjögren’s syndrome, should we sign? (2016) (3)
FRI0422 Successful dose reduction of tnf-alpha blocking agents in ankylosing spondylitis patients with stable low disease activity (2013) (3)
Addressing the clinical unmet needs in primary Sjögren’s Syndrome through the sharing, harmonization and federated analysis of 21 European cohorts (2022) (3)
10-year follow-up of patients with rheumatoid arthritis and secondary Sjögren's syndrome or sicca symptoms in daily clinical practice. (2020) (3)
Proportions of B-cell subsets are altered in incomplete systemic lupus erythematosus and correlate with interferon score and IgG levels (2020) (3)
Childhood-onset of primary Sjogren syndromePhenotypic characterization at diagnosis of 158 children (2020) (3)
Towards personalized treatment in primary Sjögren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment (2015) (3)
Comment on: Diagnostic accuracies of sialography and salivary ultrasonography in Sjögren's syndrome patients: a meta-analysis. by Song and Lee (2014). (2015) (3)
Abatacept Reduces Disease Activity In Early Primary Sjogren's Syndrome (2013) (2)
OP0040 Integration of salivary-gland ultrasonography in classification criteria for primary sjÖgren's syndrome: an international vignette-based study (2017) (2)
LEVELS OF SOLUBLE ADHESION MOLECULES DURING DISEASE RELAPSES OF SYSTEMIC LUPUS-ERYTHEMATOSUS - A LONG-TERM PROSPECTIVE-STUDY (1994) (2)
EULAR Sjögren's syndrome study group: an eSSential way to address the unmet needs of the disease. (2020) (2)
Persistent low complement levels and increased interferon gene expression are predictive for disease progression in patients with incomplete systemic lupus erythematosus. (2022) (2)
Is Ultrasonography Of Salivary Gland a Validate Tool In Sjogren Syndrome? Study 1 (2013) (2)
POS0193 EVALUATION OF CRESS IN THE PHASE 2 RANDOMISED PLACEBO-CONTROLLED STUDY OF SEQUENTIAL BELIMUMAB/RITUXIMAB ADMINISTRATION IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME (2022) (2)
The measurement of serum salivary isoamylase as a clinical parameter in Sjögren's syndrome. (2002) (2)
Identification of Clinically and Pathophysiologically Relevant Rheumatoid Factor Epitopes by Engineered IgG Targets (2020) (2)
Patient-reported change of sensibility and pain after parotid and labial gland biopsy applied for primary Sjögren's syndrome diagnostics: one-year follow-up study. (2018) (2)
Prevalence of systemic lupus erythematosus-related symptoms assessed by using the Connective Tissue Disease Screening Questionnaire in a large population-based cohort (2021) (2)
Long-term abatacept treatment for 48 weeks in patients with primary Sjögren's syndrome: The open-label extension phase of the ASAP-III trial. (2022) (2)
(Re)Treatment with rituximab inpatients with active primary Sjogren's Syndrome (2006) (2)
Novel approaches for rescuing function of the salivary gland epithelium in primary Sjögren's syndrome. (2020) (2)
OP0049 Presence of ACPA in a Large (>40.000) Population Based Cohort from the Netherlands (2015) (2)
Rituximab treatment in Sjogren's syndrome: Clinical-histological evidence of the efficacy of B-cell depletion (2006) (2)
Dehydroepiandrosterone in primary Sjogren's syndrome: A placebo controlled trial. (2006) (2)
OP0120 Influence of epidemiology and ethnicity on systemic expression of primary sjÖgren syndrome in 9974 patients (2018) (2)
Immunogenicity and safety of COVID-19 vaccination in patients with primary Sjögren’s syndrome (2022) (2)
Modification of the Classification Criteria for Primary Sjogren Syndrome: An International Vignette Survey (2017) (2)
Senescent progenitor cells in the skin of patients with cutaneous lupus erythematosus. (2021) (2)
Fatigue in primary Sjögren's syndrome is associated with an objective decline in physical performance, pain and depression. (2022) (1)
OP0040 Comparison of Radiographic Damage of the Zygapophyseal Joints and the Vertebral Bodies of the Cervical Spine in Patients With Ankylosing Spondylitis Before and After 4 Years Of Tnf-Alpha Blocking Therapy (2015) (1)
AB0705 EULAR sjÖgren’s syndrome disease activity index (ESSDAI) is sensitive to show treatment efficacy of rituximab in patients with primary sjÖgren’s syndrome (2013) (1)
Systemic Sjögren presenting without sicca syndrome : characterization of 240 patients according to the new 2017 ACR/EULAR Classification Criteria (2018) (1)
OP0126 LYMPHOMA ARISING AT THE TIME OF DIAGNOSIS OF PRIMARY SJÖGREN SYNDROME: A HIGHLY-ACTIVE SYSTEMIC SUBSET OF THE DISEASE (2019) (1)
Efficacy and Safety of Abatacept in Patients with Early Active Primary Sjogren's Syndrome - Open-label Extension Phase of a Randomized Controlled Phase III Trial (2019) (1)
Ultrasonography of Major Salivary Glands in Patients Suspected with Primary Sjogren's Syndrome : Comparison with Salivary Gland Biopsy and Classification Criteria (2016) (1)
FRI0366 A pilot study on ischemia and reperfusion injury during a raynaud's attack: sequential assessment of redox stress parameters in a unique cooling and rewarming experiment (2017) (1)
THU0077 Prevalence of Obesity and the Relation to Disease Activity, Physical Function, and Quality of Life in Patients with Axial Spondyloarthritis (2014) (1)
Parotid salivary sodium levels of Sjögren's syndrome patients suggest B-cell mediated epithelial sodium channel disruption. (2021) (1)
Stumbles in Sjögren's syndrome drug development: where to look for the next big leap? (2020) (1)
OP0177 Bcl6 identifies ectopic germinal centres in salivary gland biopsies in primary sjÖgren’s syndrome patients (2018) (1)
Decreased BAFF Receptor Expression and Unaltered B Cell Receptor Signaling in Circulating B Cells from Primary Sjögren’s Syndrome Patients at Diagnosis (2022) (1)
Sexual Dysfunction and Vaginal Dryness Are Common in Female Patients with Early, Active Primary Sjogren's Syndrome (2017) (1)
Clinical determinants of vaginal dryness in patients with primary Sjögren's syndrome. (2021) (1)
THU0681 Baseline ESSDAI/DAS scores in 8061 patients with primary sjÖgren syndrome: characterization of systemic disease (2017) (1)
Systems Biology Analysis of Sjögren’s Syndrome and MALT Lymphoma Development in Parotid Glands (2008) (1)
Correspondence on ‘Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised controlled trial’ (2021) (1)
Is the Oral Microbiome Involved in the Pathogenesis of Sjogren's Syndrome? (2017) (1)
Capillary microscopy is a potential screening method for connective tissue disease in children with Raynaud’s phenomenon (2022) (1)
Primary Sjogren's syndrome: Retreatment with rituximab and long-term follow-up. (2006) (1)
Role of interaction between B cells and epithelial cells in pSS (2020) (1)
Development and performance of the Clinical Trials ESSDAI (ClinTrialsESSDAI), consisting of frequently active clinical domains, in two randomised controlled trials in primary Sjögren's syndrome. (2021) (1)
Health-related quality of life, employment and disability in patients with Sjo¨gren’s syndrome (2009) (1)
Current insights into the relationship between the gut microbiome and Sjögren’s syndrome (2020) (1)
Patient Acceptable Symptom State (PASS) in patients with primary Sjögren's syndrome in daily clinical practice. (2022) (1)
Germinal Centers Disappear in Parotid Gland Tissue after Treatment of Primary Sjogren's Syndrome with Abatacept (2015) (1)
Assessing recovery after cold challenge and thumb involvement can help to rule out systemic sclerosis in patients presenting with Raynaud’s phenomenon (2020) (1)
Safety and efficacy of SARS-CoV-2 vaccination in 1237 patients with primary Sjögren syndrome. (2022) (1)
Treatment of patients with primary Sjogren's syndrome with rituximab is efficient according to the EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) (2012) (1)
SAT0270 Ultrasonography of major salivary glands in juvenile sjÖgren's syndrome – preliminary findings in a multi-center study (2017) (1)
Chemistry of acetylenic ethers XLIII: Reactions of oximes with ethoxyethyne (2010) (1)
Lymphoepithelial lesions in the salivary glands of primary Sjögren's syndrome patients: the perfect storm? (2022) (1)
Identification of Lifelines participants at high risk for development of rheumatoid arthritis (2017) (1)
THU0239 Drug Survival and Clinical Efficacy of 7 Years Etanercept Treatment in Patients with Ankylosing Spondylitis: Results from the Glas Cohort (2015) (1)
Extraskeletal Manifestations in Axial Spondyloarthritis Are Associated With Worse Clinical Outcomes Despite the Use of Tumor Necrosis Factor Inhibitor Therapy (2021) (1)
Prevalence Of Overweight and Obesity and The Relation To Disease Activity, Physical Function and Quality Of Life In Patients With Axial Spondyloarthritis (2013) (1)
Low Mutational Burden of Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue in Patients with Primary Sjogren’s Syndrome (2022) (1)
[Bilateral swelling of the parotid glands as part of a systemic disease]. (2004) (1)
[Sjögren's syndrome. Consequences for oral health]. (1997) (1)
Undernutrition and sarcopenic obesity: underrecognised conditions in patients with Sjögren's syndrome? (2021) (1)
Original Clinical Research (2016) (1)
Myxovirus Resistance Protein A Is a Useful Additional Histological Marker in Suspected Cutaneous Lupus Erythematosus (2020) (1)
Under-nutrition and sarcopenic obesity: under-recognised conditions in patients with Sjögren's syndrome? (2021) (1)
FDG-PET/CT discriminates between patients with and without lymphomas in primary Sjögren's syndrome. (2023) (0)
Bosentan and its effects on endothelial dysfunction in patients with severe raynaud's phenomenon in systemic sclerosis (2007) (0)
POS1010 SPINAL RADIOGRAPHIC PROGRESSION AND ITS ASSOCIATION WITH PROGRESSION TO ANKYLOSING SPONDYLITIS IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS. (2022) (0)
APRIL and BAFF Levels After Rituximab Treatment in Patients with Primary Sjogren's Syndrome: A Placebo-Controlled Clinical Trial (2011) (0)
Antibodies to double-stranded DNA in systemic lupus erythematosus. Parameter for disease activity and treatment (1996) (0)
SAT0354 Nsaid Use in Patients with Ankylosing Spondylitis Treated with and without Tnf-Alpha Blocking Therapy during 2-Year Follow-Up in Daily Clinical Practice (2014) (0)
EVALUATING HIP JOINTS AND ENTHESES WITH POWER DOPPLER ULTRASOUND IN PATIENTS WITH ANKYLOSING SPONDYLITIS BEFORE AND AFTER 6 MONTHS OF TNF-alpha BLOCKING THERAPY IN DAILY CLINICAL PRACTICE (2014) (0)
Experimental Therapies in Sjögren’s Syndrome (2011) (0)
Dysbiosis of the Oral Microbiome in Patients with Primary Sjogren's Syndrome (2018) (0)
POS0454 DIGITAL IMAGE ANALYSIS OF INTRAEPITHELIAL B-LYMPHOCYTES AS AN OBJECTIVE ALTERNATIVE TO ASSESS LYMPHOEPITHELIAL LESIONS IN SALIVARY GLANDS OF SJÖGREN’S SYNDROME PATIENTS (2022) (0)
Presence of Germinal Centers at Baseline Is Associated with Clinical Response of Glandular Essdai Domain after Abatacept Treatment in Primary Sjogren's Syndrome. (2014) (0)
THU0239 IDENTIFICATION OF BIOMARKERS AND IMMUNE PATHWAYS FOR PERSONALIZED DRUG TARGETING IN PATIENTS WITH NEWLY DIAGNOSED PRIMARY SJÖGREN’S SYNDROME (2019) (0)
ASSESSING PHYSICAL ACTIVITY IN AXIAL SPONDYLOARTHRITIS PATIENTS : MODIFICATION OF THE SQUASH (2016) (0)
SALIVARY ENZYME IN SERUM 63 T I THE PERFORMANCE OF SERUM SALIVARY ISOAMYLASE AS A CLINICAL PARAMETER IN SJÖGREN ’ S SYNDROME (2001) (0)
LONG-TERM FOLLOW-UP OF PATIENTS WITH ANTI-RNP ANTIBODIES (1992) (0)
Lymphoproliferation and Lymphoma in Sjögren’s Syndrome (2011) (0)
POS0754 PATIENT ACCEPTABLE SYMPTOM STATE (PASS) IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME IN DAILY CLINICAL PRACTICE (2022) (0)
Clinical Aspects of Sjögren's (2018) (0)
FRI0142 Patient-Reported Disease Activity and Outcome in Male versus Female Patients of the Groningen Leeuwarden Axial Spondyloarthritis (GLAS) Cohort (2013) (0)
FRI0015 B-cell depletion modulates T-helper cell balance in patients with primary sjÖgren’s syndrome (2013) (0)
P100 Proportions of B cell subsets are altered in incomplete lupus erythematosus patients and correlate with interferon score and IgG levels (2020) (0)
SAT0419 Gender Differences in Disease Activity, Physical Function and Quality of Life in Patients with Ankylosing Spondylitis Treated with TNF-α Inhibitors (2016) (0)
SAT0418 The Effect of Bisphosphonates on Bone Mineral Density in Patients with Ankylosing Spondylitis in Daily Clinical Practice (2016) (0)
[Swelling of lips as a first sign of acromegaly]. (2004) (0)
POS0758 REDUCED CENTRAL NERVOUS SYSTEM DRIVE IN PRIMARY SJÖGREN’S SYNDROME IS ASSOCIATED WITH OBJECTIVE DECLINE IN MOTOR PERFORMANCE AND SELF-REPORTED FATIGUE (2022) (0)
AB0462 BMI IS ASSOCIATED WITH BOTH DISEASE ACTIVITY AND TNF-α INHIBITOR SERUM TROUGH LEVELS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS ON LONG-TERM TREATMENT WITH TNF-α INHIBITORS (2021) (0)
THU0277 HOW THE AGE AT DIAGNOSIS MODIFIES THE PHENOTYPE OF PRIMARY SJÖGREN SYNDROME: ANALYSIS IN 11,420 PATIENTS (BIG DATA SJÖGREN PROJECT) (2019) (0)
Maturity of circulating antibody-secreting cells is associated with disease features in primary Sjögren's syndrome. (2022) (0)
FRI0432 Single-port thoracoscopic sympathicotomy for treatment resistant raynaud’s phenomenon. first report of a novel minimally-invasive endoscopic technique (2018) (0)
Recent insights in the potential role of imaging modalities for diagnosing patients with primary Sjögren's syndrome. (2020) (0)
Senescence of salivary gland stem cells in primary Sjogren's syndrome : the cause of persistent hyposalivation? (2018) (0)
MALE AND FEMALE PATIENTS WITH AXIAL SPONDYLOARTHRITIS EXPERIENCE DISEASE ACTIVITY DIFFERENTLY: RESULTS FROM THE GLAS COHORT (2014) (0)
THU0477-HPR Fatigue in psychosocial subgroups of patients with sjÖgren’s syndrome (2013) (0)
Ultrasound Scoring of One Parotid and One Submandibular Gland in Primary Sjogren's Syndrome - Further Increasing Feasibility in Outpatient Clinics (2017) (0)
OP0286 DEVELOPMENT AND PRELIMINARY VALIDATION OF THE SJÖGREN’S TOOL FOR ASSESSING RESPONSE (STAR): A CONSENSUAL COMPOSITE SCORE FOR ASSESSING TREATMENT EFFECT IN PRIMARY SJÖGREN’S SYNDROME (2022) (0)
Digital image analysis of intraepithelial B-lymphocytes to assess lymphoepithelial lesions in salivary glands of Sjögren’s syndrome patients (2022) (0)
SAT0251 Bridging Syndesmophytes and Low Bone Mineral Density are Associated with Higher Bone Turnover in Ankylosing Spondylitis Patients with Active Disease (2013) (0)
How the different systemic organ involvements are overlapped in patients with primary Sjogren syndrome: analysis using a mathematical model (2018) (0)
A2.18 Dysregulated BTK expression in peripheral blood B lymphocytes in systemic autoimmune disease (2015) (0)
THU0581 Spousal Protective Buffering is Related to a Lower Physical and Mental Quality of Life in Patients with Sjögren’s Syndrome (2013) (0)
List of Contributors (2019) (0)
Numbers of B-lymphocytes increase when formation of lymphoepithelial lesions progresses in salivary glands of primary Sjogren's syndrome patients (2018) (0)
AB0610 Nailfold capillary microscopy and low body mass index in raynaud's phenomenon patients (2017) (0)
University of Groningen Early atherosclerosis in systemic sclerosis and its relation to disease or traditional risk factors Hettema, (2015) (0)
AB0692 ASSESSING RECOVERY TIME AFTER COLD CHALLENGE AND THUMB INVOLVEMENT CAN HELP TO RULE OUT SYSTEMIC SCLEROSIS IN PATIENTS PRESENTING WITH RAYNAUD’S PHENOMENON (2019) (0)
POS0457 LABIAL AND PAROTID SALIVARY GLAND HISTOPATHOLOGY IN PRIMARY SJÖGREN’S SYNDROME (2022) (0)
FRI0116 Prevalence of Vertebral Fractures and the Relation to Clinical and Radiological Outcome in Ankylosing Spondylitis Patients with Active Disease (2014) (0)
OP0240 ASSESSMENT OF PULSE WAVE VELOCITY IN SYSTEMIC SCLEROSIS: POTENTIAL BENEFICIAL EFFECTS OF BOSENTAN ON FOREARM ARTERIAL STIFFNESS? AN EXPLORATORY STUDY (2019) (0)
Patient-Tailored Dose Reduction Of Tumor Necrosis Factor-Alpha Blocking Agents In Ankylosing Spondylitis Patients With Stable Low Disease Activity (2013) (0)
Can ultrasound of the major salivary glands differentiate primary Sjögren’s syndrome from other systemic diseases with salivary gland involvement? (2017) (0)
Mycophenolate mofetil prevents the development of a clinical relapse in SLE patients at risk: an open pilot study (2002) (0)
Subject Index Vol. 41, 1999 (1999) (0)
SAT0343 Spinal Radiographic Progression during 6 Years of Tnf-Alpha Blocking Therapy in Patients with Ankylosing Spondylitis: Results from the GLAS Cohort (2014) (0)
OP0042 THE TRANSCRIPTOME OF PAIRED MINOR AND MAJOR SALIVARY GLAND TISSUE IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME: TWO OF A KIND? (2020) (0)
[Determination of antibodies against double-stranded DNA; when and which test?]. (1991) (0)
Primary Sjogren's syndrome (2006) (0)
The lacrimal gland in Sjögren's syndrome: can we unravel its mystery using ultrasound? (2022) (0)
Quality of life, employment and disability in patients with Sjogren's syndrome (2008) (0)
B-Cell Depletion Modulates T-Helper Cell Balance In Patients With Primary Sjogren's Syndrome (2013) (0)
Letter to the editor: Prevalence of connective tissue disease autoantibodies in a large longitudinal population-based cohort from the Netherlands. (2022) (0)
IFN Gene Expression Correlates with Frequency of Circulating Switched Memory B-Cells in Patients with Incomplete Systemic Lupus Erythematosus (2018) (0)
POS0031 THE PREVALENCE OF INFLAMMATORY BACK PAIN AND HLA-B27 IN A LARGE POPULATION-BASED COHORT IN THE NETHERLANDS (2021) (0)
P17 ARTERIAL STIFFNESS OF THE FOREARM IS ASSOCIATED WITH NAILFOLD CAPILLARY COUNT IN SYSTEMIC SCLEROSIS: A NOVEL MARKER OF EARLY VASCULOPATHY? (2018) (0)
Low Mutational Burden of Extra Nodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue in Patients with Primary Sjogren's Syndrome (2021) (0)
Composite endpoints for Sjögren's Syndrome – Authors' reply (2021) (0)
NSAM USE IN PATIENTS WITH ANKYLOSING SPONDYLITIS TREATED WITH AND WITHOUT TNF- a BLOCKING THERAPY DURING 2-YEAR FOLLOW-UP (2014) (0)
Immunisation with Coronavirus-2 vaccines induces potent antibody responses and does not aggravate the lymphocyte compartment of primary Sjögren's syndrome patients. (2022) (0)
University of Groningen Rapid free thiol rebound is a physiological response following cold-induced vasoconstriction in healthy humans, primary Raynaud and systemic sclerosis (2019) (0)
PO.2.30 IGG/IGM autoantibody ratios do not relate to progression from incomplete systemic lupus erythematosus to systemic lupus erythematosus (2022) (0)
AB0175 Dysregulation of nf-Κb in glandular epithelial cells results in sjÖgren’s-like features (2018) (0)
Senescent progenitor cell depletion as a potential therapy for hyposalivation in primary Sjogren's syndrome? (2019) (0)
The parotid gland in primary Sjogren's syndrome : comparison of ultrasound, histopathology and saliva production in the diagnostic work-up (2018) (0)
PO.8.180 Biomarkers before conception related to adverse pregnancy outcomes in patients with systemic lupus erythematosus and primary sjögren’s syndrome: a retrospective cohort study (2022) (0)
FRI0377 Abnormal nailfold capillaroscopy pattern is common in patients with connective tissue disease and associated with organ involvement (2017) (0)
Cyclophosphamide monotherapy for scleroderma lung disease (2004) (0)
Clinical and epidemiological research (2011) (0)
Frequencies and Numbers of Circulating IL-10 Producing Regulatory B Cells Are Not Disturbed in Pss-Patients but Correlate Negatively with the EULAR Sjogren Syndrome Disease Activity Score (ESSDAI) (2012) (0)
P58 SINGLE-PORT THORACOSCOPIC SYMPATHICOTOMY FOR TREATMENT RESISTANT RAYNAUD’S PHENOMENON: FIRST REPORT OF A NOVEL MINIMALLY INVASIVE ENDOSCOPIC TECHNIQUE (2018) (0)
resolve the long debate on the issue syndrome : we actually need to definitively Classification criteria for Sjögren ' s (2013) (0)
AB0153 Reduced Regenerative Potential of Salivary Gland Stem Cells in Primary Sjögren's Syndrome (2016) (0)
FRI0454 Arterial stiffness of the forearm is associated with nail-fold capillary count in ssc: a novel marker of early vasculopathy? (2018) (0)
CRESS ASSESSMENT IN SJOGREN’S SYNDROME A COMMENTARY (2021) (0)
Differences in presentation between paediatric- and adult-onset primary Sjögren's syndrome patients. (2021) (0)
SAT0457 SjÖgren big data project, the first example of data sharing in autoimmune diseases: analysis of 10475 worldwide patients (2018) (0)
Why and how: all you need to know of parotid gland biopsies in Sjögren's Syndrome (2015) (0)
Oral and ocular comparison (2001) (0)
Clinical Relevance of Serum Free Light Chain Level As Biomarker in Primary Sjogren's Syndrome (2017) (0)
Chapter 2 Xerostomia (2018) (0)
Selection of study endpoints and patients for clinical trials in primary Sjögren's syndrome. (2022) (0)
Myxovirus Resistance Protein a Is a Useful Additional Histological Marker for Cutaneous Lupus Erythematosus (2019) (0)
The impact of primary Sjo¨gren’s syndrome on female sexual function RHEUMATOLOGY (2015) (0)
Rituximab in the treatment of primary Sjogren's syndrome: A phase II study (2005) (0)
The Presence of Extractable Nuclear Antigens (ENA) Antibodies in a Large Population-based Cohort from the Netherlands and Their Association with Known Risk Factors for Systemic Lupus Erythematosus and Primary Sjogren Syndrome (2019) (0)
OP0175 Interferon signature might serve as early biomarker for development of lupus and correlates strongly with myxovirus-resistance protein a (2018) (0)
AB0517 Impaired Sexual Function in Women with Primary SjÖGren's Syndrome (2014) (0)
THU0706 Presence of extractable nuclear antigens (ENA) antibodies in a large population-based cohort from the netherlands (2018) (0)
AB0117 IMMUNE CELL IMBALANCES IN PLACENTAS OF SYSTEMIC LUPUS ERYTHEMATOSUS AND SJÖGREN’S SYNDROME PATIENTS (2022) (0)
FRI0263 Characterisation of epithelium-associated fcrl4+ b cells from parotid glands of patients with sjÖgren’s syndrome using single cell rna sequencing (2018) (0)
Accuracy of Ultrasonographic Imaging of Major Salivary Glands in Diagnosing Sjogren's Syndrome: A Systematic Review and Meta-Analysis (2015) (0)
Baseline Characteristics of Parotid Gland Histopathololgy Predict Responsiveness of Patients with Primary Sjogren's Syndrome to Rituximab Treatment (2015) (0)
Clinical and immunological disease patterns of primary Sjogren syndrome driven by gender and age at diagnosis (2018) (0)
Author index (1987) (0)
Patient-reported post-operative change of sensibility and pain after parotid and labial gland biopsy applied in the diagnostics of primary Sjogren's syndrome: one year follow-up study (2018) (0)
Dental implants : a good treatment option in patients with Sjogren's syndrome (2014) (0)
Clinical signiﬁcance of quantitative immunohistology in labial salivary glands for diagnosing Sjo¨gren’s syndrome (2006) (0)
University of Groningen The value of rituximab treatment in primary Sjögren's syndrome (2017) (0)
POS0738 IMMUNOGENICITY AND SAFETY OF COVID-19 VACCINATION IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME (2022) (0)
Ultrasonography of major salivary glands in juvenile Sjogren's syndrome : an international multicentre study (2018) (0)
P14: REFERENCE VALUES OF THE WEST SPANISH POPULATION OF THE HEMODYNAMIC INDICES EVALUATED WITH A NEW WRIST WORN DEVICE (0)
Comparison of sensitivity to change of 2 clinical measures of lupus disease activity : A longitudinal prospective study. (1996) (0)
P101 Hydroxychloroquine suppresses IFN-inducible genes and BAFF in patients with incomplete and new onset systemic lupus erythematosus (2020) (0)
Development of New Radiographic Vertebral Fractures in Patients with Ankylosing Spondylitis during 4 Years of TNF-alpha Blocking Therapy (2014) (0)
AB0658 Influence of Known Risk Factors on Spinal Radiographic Progression in Ankylosing Spondylitis Patients Receiving Long-Term Treatment with TNF Inhibitors: Results from The Glas Cohort (2016) (0)
SAT0431 The acr-eular classification criteria in primary sjÖgren’s syndrome: the contributing role of ultrasound (2018) (0)
THU0241 Presence of Germinal Centers in Diagnostic Biopsies of Primary Sjögren's Syndrome Patients Is Not A Risk Factor for The Development of Parotid Malt Lymphomas (2016) (0)
FRI0413 Clinical Risk Factors for The Presence and Development of Vertebral Fractures in Patients with Ankylosing Spondylitis (2016) (0)
P56: CENTRAL PULSE PRESSURE IS ASSOCIATED WITH RETINAL ARTERIOLAR WALL THICKNESS AND WALL CROSS SECTIONAL AREA AS EVALUATED BY ADAPTIVE OPTICS (0)
THU0471-HPR Crying without tears: Dimensions of crying and relations with ocular dryness in patients with sjÖgren’s syndrome (2013) (0)
AB0082 PERSISTENT LOW COMPLEMENT LEVELS AND INTERFERON GENE UPREGULATION ARE PREDICTIVE FOR DISEASE PROGRESSION IN PATIENTS WITH INCOMPLETE SYSTEMIC LUPUS ERYTHEMATOSUS (2021) (0)
Translational Research in Sjögren’s Syndrome (2018) (0)
Chapter 32 – Management of Sjögren Syndrome in Patients with SLE (2013) (0)
PS1:5 Interferon signature is increased in incomplete sle and correlates with mxa and ip-10 levels (2018) (0)
POS1014 CENTRAL SENSITIZATION HAS MAJOR IMPACT ON QUALITY OF LIFE IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS (2021) (0)
How ethnicity modifies systemic activity of primary Sjögren syndrome : analysis of baseline ESSDAI scores in a multi-ethnic international cohort (2018) (0)
P I PRIMARY SIALOANGIECTASIA : A DIAGNOSTIC PITFALL IN SJÖGREN ' S SYNDROME . CASE REPORT (2001) (0)
[Bilateral swelling of the parotid glands as part of a systemic disease]. (2004) (0)
Dehydroepiandrosterone in primary Sjogren's syndrome (2006) (0)
Vol. 41, 1999 (1999) (0)
SAT0416 Ankylosing spondylitis disease activity score (ASDAS) is associated with nsaid use over time (2017) (0)
University of Birmingham Efficacy of Epratuzumab, an AntiCD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients with Associated Sjögren's Syndrome: (2018) (0)
[Antibiotic prophylaxis and immune-compromised patients]. (2019) (0)
Early Reconstitution of Autoreactive B-Cells After Rituximab Treatment in Primary Sjogren's Syndrome (2011) (0)
Health Professionals in Rheumatology Abstracts THU0477-HPR FATIGUE IN PSYCHOSOCIAL SUBGROUPS OF PATIENTS WITH SJÖGREN’S SYNDROME (0)
University of Groningen Germinal centres in diagnostic labial gland biopsies of patients with primary Sjogren's syndrome are not predictive for parotid MALT lymphoma development Haacke, (2017) (0)
SLEEP AND NIGHTLY ORAL DRYNESS AS POTENTIAL THERAPEUTIC TARGETS TO REDUCE FATIGUE IN SJOGREN'S SYNDROME (2013) (0)
SP0113 Primary SjöGren’s Syndrome: What is New in 2012 to 2013? (Win) (2013) (0)
University of Groningen Development and preliminary validation of the Sjögren's Tool for Assessing Response (STAR) Seror, (2022) (0)
Identifying relevant determinants of in-hospital time to diagnosis for ANCA-associated vasculitis patients (2022) (0)
FRI0310 Is ultrasonography of salivary gland a validate tool in sjögren syndrome?-study 1: interobserver reliability (2013) (0)
Addition of salivary gland ultrasound increases the feasibility of the ACR-EULAR classification criteria in primary Sjogren's syndrome (2018) (0)
Can salivary gland ultrasonography replace salivary gland biopsy in the diagnosis of Sjögren's syndrome? (2022) (0)
Serum amyloid P component (SAP) binds to late apoptotic cells and mediates their phagocytosis by macrophages (2002) (0)
SAT0683 A north-south worldwide gradient in systemic activity of primary sjÖgren syndrome: increased severe disease in patients from southern countries (2018) (0)
AB0662 Inflammatory Power Doppler Ultrasound Lesions of the Entheses and Hip Joints in Patients with Ankylosing Spondylitis before and after 6 Months of Tnf-α Blocking Therapy in Daily Clinical Practice (2014) (0)
The Parotid Gland in Primary Sjögren Syndrome: Association of Ultrasound, Histopathology and Saliva Production in the Diagnostic Workup (2018) (0)
P27 Myxovirus resistance protein A is a useful additional histological marker for cutaneous lupus erythematosus (2020) (0)
UvA-DARE ( Digital Academic Repository ) Sialometry and sialochemistry : a nonivasive approach for diagnosing Sjögren ' s syndrome (2001) (0)
Reply (2020) (0)
SAT0246 The Prevalence and Incidence of Radiographic Zygapophyseal Joint Involvement in Patients with Ankylosing Spondylitis Before and During 4 Years of TNF-Alpha Blocking Therapy (2015) (0)
Change in disease activity is associated with TNF-α inhibitor serum levels in patients with axial spondyloarthritis in daily clinical practice. (2021) (0)
FRI0426 Response of the reactive species interactome to hypothermia induced raynaud’s attack in primary raynaud and systemic sclerosis (2018) (0)
P270 Treatment of MALT lymphoma in Sjögren's syndrome: a retrospective clinical study and a proposal for treatment guidelines (2007) (0)
SAT0257 Nsaid Use in Relation to Disease Activity in Patients with Ankylosing Spondylitis Treated with and Without TNF-α Blocking Therapy in Daily Clinical Practice (2015) (0)
SAT0287 Ethnic Differences Strongly Influence The Phenotypic Expression of Primary Sjögren: Study of 7887 Patients from 20 Countries on 5 Continents (EULAR-SS Task Force Big Data Sjögren Project) (2016) (0)
Clinical Phenotyping of Patients with Primary Sjogren's Syndrome Using Salivary Gland Ultrasonograhpy (2019) (0)
POS0145 CLINICAL RESPONSE TO RITUXIMAB IS ASSOCIATED WITH PREVENTION OF B-CELL DRIVEN SALIVARY GLAND INFLAMMATION AND EPITHELIAL RESTORATION AS REVEALED BY MOLECULAR PATHOLOGY: RESULTS FROM THE TRACTISS TRIAL IN PRIMARY SJOGREN’S SYNDROME (2022) (0)
AB0550 PHENOTYPE OF BIOPSY-PROVEN PATIENTS WITH PRIMARY SJÖGREN SYNDROME LACKING RO AUTOANTIBODIES: HIGH FREQUENCY OF DRYNESS SYMPTOMS WITH LOW SYSTEMIC ACTIVITY (BIG DATA SJÖGREN PROJECT) (2019) (0)
FRI0377 Abatacept Reduces Circulating Effector Memory T-Helper Cells in Patients with Primary SjÖGren's Syndrome (2014) (0)
POS1012 PATIENT CHARACTERISTICS AND CLINICAL ASSESSMENTS ASSOCIATED WITH PROGRESSION FROM NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS TO ANKYLOSING SPONDYLITIS (2022) (0)
THU0284 Predicting survival in 6240 patients with primary sjÖgren' syndrome (big data sjÖgren project) (2017) (0)
OP0010 A MORE MATURE PLASMA CELL AND PLASMABLAST COMPARTMENT IS ASSOCIATED WITH DISEASE MANIFESTATION IN PRIMARY SJÖGREN’S SYNDROME (2022) (0)
University of Groningen Sjogren ' s syndrome (2010) (0)
SAT0190 Reduction of serum immunoglobulin free light chains upon rituximab (anti-CD20) treatment correlates with decreased disease activity in patients with primary sjögren’s syndrome (2013) (0)
THU0352 Worldwide Heterogeneous Diagnostic Approach To Primary Sjögren Syndrome in 8315 Patients (EULAR-SS Task Force Big Data Sjögren Project) (2016) (0)
Interferon-related Chemokine Cxcl-10(Ip-10) In Incomplete Systemic Lupus Erythematosus; A Potential Predictive Biomarker For Disease Progression? (2016) (0)
Characterization of Dominant B- and Plasma Cell Clones in Patients with Primary Sjogren's Syndrome and Patients with Sicca Syndrome (2012) (0)
VALUE OF IGA ANTIPHOSPHOLIPID ANTIBODIES IN SYSTEMIC LUPUS ERYTHEMATOSUS AND UNEXPLAINED PREGNANCY MORBIDITY (2016) (0)
FRI0210 Extra-articular manifestations are associated with worse quality of life and clinical outcome in patients with axial spondyloarthritis (2018) (0)
Skin autofluorescence, as measure of cumulative metabolic and oxidative stress, in relation to lipids in patients with systemic sclerosis (2008) (0)
SAT0301 Vasospastic Severity and Digital Ischemia during Cooling is Related to Nail-Fold Capillaroscopic Pattern in Patients with Secondary Raynaud Phenomenon and Systemic Sclerosis (2014) (0)
SAT0277 Clinical, Ultrasound and Radiographic Evaluation of the Hip Joints in Ankylosing Spondylitis Patients with Active Disease (2015) (0)
POS1006 DIAGNOSIS OF AXIAL SpA AND ADDITIONAL FEATURES IN HLA-B27 POSITIVE INDIVIDUALS REPORTING CHRONIC INFLAMMATORY BACK PAIN: DATA FROM A LARGE DUTCH POPULATION-BASED COHORT (2022) (0)
Response to: "A combination of complement activation products with autoantibodies predicts transition of probable lupus to systemic lupus erythematosus". (2020) (0)
SAT0302 SINGLE-PORT THORACOSCOPIC SYMPATHICOTOMY IS VERY EFFECTIVE FOR TREATMENT RESISTANT RAYNAUD’S PHENOMENON: A ONE MONTH FOLLOW-UP (2019) (0)
SALIVARY GLAND FUNCTION 55 A I A NEW SCREENING DEVICE : DETECTION OF SJÖGREN ’ S SYNDROME ON A DROPLET SALIVA (2018) (0)
Abatacept reduces Circulating Effector Memory T-Helper Cells in Patients with Primary Sjogren's Syndrome. (2014) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Hendrika Bootsma?

Hendrika Bootsma is affiliated with the following schools:

Hendrika Bootsma's Academic­Influence.com Rankings

Hendrika Bootsma's Degrees

Why Is Hendrika Bootsma Influential?

Hendrika Bootsma's Published Works

Published Works

What Schools Are Affiliated With Hendrika Bootsma?

Hendrika Bootsma's AcademicInfluence.com Rankings